Send feedback

TP53 p.Pro13Ser

c.37C>T · rs1060501208 · VCV406604

Uncertain significance Expert panel
Classification
Uncertain significance
ClinVar
Review
Expert panel ★★★☆
ClinVar · 6 submitters
AlphaMissense
likely benign
0.2337 · ACMG-weighted
gnomAD v4.1
Rare
very rare (popmax 0.00334%, amr)
Missense predictors
1/3 damaging
AlphaMissense, REVEL, SaProt
Conditions
2
Li-Fraumeni syndrome

ClinGen expert panel — TP53 VCEP

Uncertain Significance for Li-Fraumeni syndrome. Applied ACMG criteria (verbatim):

PM2_Supporting PS4_Moderate PP4 BS3 BS2_Supporting BP4

Curation rationale (ClinGen, verbatim)

The NM_000546.6(TP53):c.37C>T variant in TP53 is a missense variant predicted to cause substitution of proline by serine at amino acid 13 (p.Pro13Ser). This variant has been reported in 4 unrelated probands meeting Revised Chompret criteria. Based on this evidence, this variant scores 2 total points meeting the TP53 VCEP phenotype scoring criteria of 2-3.5 points. (PS4_Moderate; Internal lab contributors). At least one individual with this variant was found to have a variant allele fraction of 5-35%, which is a significant predictor of variant pathogenicity (PP4, PMID: 34906512, Internal lab contributor). This variant has been observed in 3 heterozygous unrelated females from the same data source with no personal history of cancer prior to age 60 years and no personal history of sarcoma at any age (BS2_Supporting; Internal lab contributor). This variant has an allele frequency of 0.000001239 (2/1613918 alleles) across gnomAD v4.1.0 which is lower than the Clingen TP53 VCEP threshold (<0.00003) for PM2_Supporting and has a subpopulation allele frequency of <0.00004 in all non-bottleneck populations with 2 or more alleles present (PM2_Supporting). In vitro assays performed in yeast and/or human cell lines showed functional transactivation and retained growth suppression activity by the majority of available assays indicating that this variant does not impact protein function (BS3; PMIDs: 12826609, 30224644). Computational predictor scores (BayesDel = 0.123287; Align GVGD Class C0) are below the recommended thresholds (BayesDel < 0.16 and > -0.008 and an Align GVGD Class ≤ 55), evidence that does not predict a damaging effect on TP53 via protein change. SpliceAI predicts that the variant has no impact on splicing (BP4). Although this variant meets the criteria to be classified as Likely Benign, the VCEP has overridden this classification to variant of uncertain significance for Li Fraumeni syndrome due to conflicting evidence: BS3, BP4, PM2_supporting, PS4_moderate, PP4, BS2_Supporting. (Bayesian Points: -2; VCEP specifications version 2.4)

ClinGen Evidence Repository → · reported verbatim, not re-tallied by Sugi Variant.

Computational evidence

Protein change
AlphaMissense0.2337likely benign
REVEL0.723pathogenic-leaning
SaProtLLR -6.03tolerated
⇒ REVEL calls this damaging; AlphaMissense and SaProt do not.
Splicing
SpliceAI—not assessed · no allele here is in the release
Constraint at this position
ConservationphyloP 7.4GERP 2.2, phastCons 1
Regional constrainto/e 0.89unconstrained · MANE · 6,982 bp · p 0.0085 · regional, not allelic
Overall
CADD22.6PHRED · no single calibrated threshold — expert panels disagree

AlphaMissense carries the ACMG weight for missense; REVEL and SaProt are independent agreement signals.

Population frequency

gnomAD v4.1 · exomes + genomes
Grpmax group 0.00334% Admixed American · 2/59,958 alleles
Filtering AF 0.000553% ClinGen BA1/BS1 input FAF95, joint · FAF99 0.000207%
Overall 0.000124% 2/1,613,918 alleles · very rare

Rarity supports pathogenicity (ACMG PM2); frequency above a disease-specific BA1/BS1 threshold argues against it. A variant frequent in one ancestry group can be near-absent in others, so a single global figure can mislead.

Variant & gene context

Gene
TP53
Protein
p.Pro13Ser
Coding
c.37C>T
MANE Select
NM_000546
dbSNP
rs1060501208
Type
single nucleotide variant
Location
chr17:7676558 (GRCh38)
Gene constraint
LOEUF 0.449 · pLI 1.00 · ClinGen HI 3/3 (gnomAD)
Structure
AlphaFold pLDDT 75.83 · 321 PDB
Residue 13
the 'interaction with ccar2' region; the 'interaction with hrmt1l2' region; the 'transcription activation (acidic)' region
Full TP53 gene report on Sugi Atlas → Gene function, pathways, protein structure, interactions & more

Disease context

Li-Fraumeni syndrome — disease report on Sugi Atlas → Associated genes, phenotypes, clinical trials & treatments

Also linked: hereditary neoplastic syndrome

For Li-Fraumeni syndrome (Orphanet):

Inheritance
Autosomal dominant
Onset
All ages
Prevalence
1-9 / 100 000 (United Kingdom)

Similar variants

Built on 18 open, versioned datasets — ClinVar, gnomAD, AlphaMissense, REVEL, ClinGen & more — plus Sugi Variant's own cross-source analysis. Source data 2026-01–2026-10, ClinVar 2026-10. Full sources & versions →

Cite Sugi Variant

Gür T. Sugi Variant: A Deterministic Per-Variant Germline Reference from a Knowledge Graph for Humans and AI Agents. 2026. doi:10.5281/zenodo.21509445. This variant: https://sugi.bio/variant/tp53-p-pro13ser (accessed [today's date]).

Preprint & method: sugi.bio/variant/method Machine-readable: this page as Markdown